Zhongchao Inc. (ZCMD) - Form 20-F Summary
Business Context and Reporting Period
Company: Zhongchao Inc. (Cayman Islands holding company)
Reporting Period: Fiscal Year Ended December 31, 2025
Primary Operations: Healthcare information, education, and training services in China via Variable Interest Entity (VIE) arrangements.
Key Segments: MDMOOC Services (medical training/education) and Sales of Patented Drugs (discontinued June 30, 2025).
Listing: Nasdaq Capital Market (Symbol: ZCMD).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenue | $11.37 million | $15.86 million | $19.43 million |
| Gross Profit | $5.12 million | $8.91 million | $8.51 million |
| Gross Margin | 45.0% | 56.2% | 43.8% |
| Net Loss | $(5.81) million | $(0.27) million | $(11.31) million |
| Operating Cash Flow | $0.85 million | $(1.47) million | $0.05 million |
| Cash & Equivalents | $8.10 million | $7.84 million | $7.55 million |
| Total Assets | $24.15 million | $25.88 million | N/A |
| Total Liabilities | $1.55 million | $1.73 million | N/A |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 28.3% to $11.37 million. This was driven by a $2.2 million drop in patient-aid project revenue and a $1.5 million drop in drug sales following the cessation of the drug retail segment (Xinjiang Pharmaceutical) on June 30, 2025.
- Increased Operating Expenses: General and Administrative (G&A) expenses surged 96.6% to $9.81 million. This increase was primarily due to a $3.7 million share-based compensation expense and a $0.8 million increase in credit loss provisions for aged receivables.
- Margin Compression: Gross margin declined from 56.2% to 45.0% due to intensified competition and higher project execution costs relative to revenue.
- Share Consolidation: A 1-for-8 share consolidation was effectuated on March 2, 2026, to regain compliance with Nasdaq minimum bid price requirements.
Guidance, Outlook, and Risks
Management Commentary: The company is optimizing its project portfolio by discontinuing low-margin or extended payment cycle projects. It ceased operations of its drug sales subsidiary to focus on core MDMOOC services. The company intends to use existing cash reserves to fund operations and explore international expansion.
Material Risks:
- VIE Structure: Operations rely on contractual arrangements with PRC entities; PRC regulatory changes could invalidate these arrangements, rendering the company's assets worthless.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including a lack of monitoring mechanisms and insufficient US GAAP expertise.
- Regulatory Environment: Significant uncertainty regarding PRC laws on overseas listings, data security (Cybersecurity Review Measures), and foreign investment restrictions.
- Customer Concentration: In 2025, four customers accounted for approximately 60.9% of total revenue.
- Delisting Risk: The company previously received notice of non-compliance with Nasdaq minimum bid price rules but regained compliance following the share consolidation.
Investor Verification Checklist
- Verify VIE Validity: Confirm the enforceability of the contractual arrangements with Zhongchao Shanghai under current PRC law.
- Assess Internal Control Remediation: Review the progress of remediation efforts for the identified material weaknesses in financial reporting.
- Monitor Customer Concentration: Evaluate the risk of revenue loss given that four customers represent over 60% of sales.
- Check Receivables Quality: Scrutinize the allowance for credit losses, which increased significantly in 2025 due to aged receivables.
- Review Nasdaq Compliance: Monitor the stock price to ensure continued compliance with the $1.00 minimum bid requirement post-consolidation.